
Biologics have shown to be a tremendous breakthrough in the treatment of a variety of diseases such as rheumatoid arthritis, cancer, diabetes and multiple sclerosis. At the same time, biologics have had a large impact on health care systems: although the systems were able to offer innovative treatments to their citizens, this came at a significant cost. These costs have become a major issue in many healthcare systems as policy makers try to balance access to innovative and effective treatments with sustainable costs for the health care system.

Therefore, availability of competing biosimilars is of great value to health care systems, and makes biologics accessible to broader patient groups and creates headroom for innovation.




UMN INDICATOR*



PATIENT PERSPECTIVE

Burden of disease at the level of the individual



^{*}the positions are indicative and meant for illustrative purposes only